Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 11/20 | 0.73 |
| ▸ | PPP5C | P53041 | 2/20 | 0.67 |
| ▸ | NPY4R | P50391 | 2/20 | 0.67 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.50 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.50 |
| ▸ | PPM1B | O75688 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334396 | 1.00 | TFPI2 (0.73) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL13311572 | 1.00 | TFPI2 (0.73) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL2330162 | 0.87 | TFPI2 (0.55) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL2330157 | 0.85 | TFPI2 (0.53) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL13311599 | 0.84 | TFPI2 (0.93) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL18073223 | 0.83 | TFPI2 (0.90) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL9880174 | 0.83 | TFPI2 (0.90) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL2332631 | 0.83 | TFPI2 (0.77) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL13311562 | 0.83 | TFPI2 (0.90) | TFPI2PPP5CNPY4RPPP2CAKDM4E | |
| SCHEMBL13001884 | 0.82 | TFPI2 (0.49) | TFPI2PPP5CNPY4RPPP2CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2870161-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | LIXTE BIOTECHNOLOGY INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2318005-B1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2124550-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY INC (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2016134257-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTER BIOTECHNOLOGY, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016014778-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2010147612-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010014141-A1 | METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009020565-A1 | USE OF PHOSPHATES TO TREAT NEUROBLASTOMAS AND MEDULLOGASTOMAS | LIXTE BIOTECHNOLOGY, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | TFPI2 4324/4885PPP5C 2709/4885NPY4R 490/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TFPI2 4843/4885PPP5C 2860/4885NPY4R 3326/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885 |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.